Compare Nerdwallet Inc (NRDS) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Revvity Inc — how do they compare? Nerdwallet Inc trades at $9.74 (market cap $625.17M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 27.2× Nerdwallet Inc's market cap, and Revvity Inc pays a 0.18% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Revvity Inc for 12 Days on average.
| NRDS | RVTY | |
|---|---|---|
Market Cap | $625.17M | $16.98B |
Volume | 1,321,316 | 1,456,900 |
Sector | Media | Health |
52-Week High | $15.93 | $157.36 |
52-Week Low | $7.58 | $82.26 |
Typical Hold Time | 45 Days | 12 Days |
Enterprise Value | $539.47M | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.79, up 7.76% with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with revenue growing from $539M in 2022 to $837M in 2025, though Q2 2026 earnings missed expectations. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81, while profitability metrics show ROE of 18.16% and net margin of 7.56%.
The stock presents a compelling growth story with accelerating revenue and improving margins, supported by 66.7% analyst buy ratings. Key risks include competitive pressure in organic search and execution challenges in maintaining earnings momentum. The positive cash flow trend and institutional support suggest potential for continued upside if the company can sustain its growth trajectory.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
